Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Sierra Leone

Sierra Leone

Sierra Leone's revenue in the Other Vaccines market is forecasted to reach US$2.46m in 2024.
The revenue is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 10.32%, leading to a market volume of US$4.02m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$24,730.00m in 2024.
Sierra Leone's demand for other vaccines is rising steadily due to increasing awareness and government initiatives.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

Sierra Leone, a country in West Africa, has been experiencing a rise in the demand for Other Vaccines.

Customer preferences: The demand for Other Vaccines in Sierra Leone has been increasing due to the growing awareness of the importance of vaccination in preventing infectious diseases. Additionally, the government has been actively promoting vaccination campaigns to improve the overall health of the population.

Trends in the market: Sierra Leone has been experiencing a trend towards the adoption of new and advanced vaccines, such as the HPV vaccine. The demand for this vaccine has been increasing due to the rising incidence of cervical cancer in the country. Additionally, there has been a trend towards the adoption of combination vaccines, which offer protection against multiple diseases in a single shot.

Local special circumstances: Sierra Leone has a high incidence of infectious diseases such as malaria, typhoid fever, and yellow fever. This has led to a high demand for vaccines that provide protection against these diseases. Additionally, the country has a high infant mortality rate, which has led to a focus on vaccination campaigns for children.

Underlying macroeconomic factors: Sierra Leone is one of the poorest countries in the world, with a low GDP per capita and a high level of poverty. This has led to a reliance on international aid to fund vaccination campaigns and purchase vaccines. Additionally, the country has a weak healthcare system, which has led to a lack of access to vaccines in some areas. However, the government has been making efforts to improve the healthcare system and increase access to vaccines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.